BeiGene has announced that the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE® in China supplied to BeiGene by Celgene Corporation, a Bristol Myers Squibb company. This suspension is based on inspection findings at CMO Fresenius Kabi’s site in Melrose Park, Illinois. As a result, BeiGene expects a disruption in ABRAXANE supply in China and is working closely with BMS to restore supply as soon as possible, including through BMS’s remediation efforts at the current manufacturing site and application to qualify an alternative manufacturing site for China supply. Learn More